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Abstract
CXCR4 is a G-protein-coupled receptor that mediates recruitment
of blood cells toward its ligand SDF-1. In cancer, high CXCR4
expression is frequently associated with tumor dissemination
and poor prognosis. We evaluated the novel CXCR4 probe
[68Ga]Pentixafor for in vivo mapping of CXCR4 expression density
in mice xenografted with human CXCR4-positive MM cell lines and
patients with advanced MM by means of positron emission tomo-
graphy (PET). [68Ga]Pentixafor PET provided images with excellent
specificity and contrast. In 10 of 14 patients with advanced MM
[68Ga]Pentixafor PET/CT scans revealed MM manifestations,
whereas only nine of 14 standard [18F]fluorodeoxyglucose PET/CT
scans were rated visually positive. Assessment of blood counts and
standard CD34+ flow cytometry did not reveal significant blood
count changes associated with tracer application. Based on these
highly encouraging data on clinical PET imaging of CXCR4 expres-
sion in a cohort of MM patients, we conclude that [68Ga]Pentixafor
PET opens a broad field for clinical investigations on CXCR4
expression and for CXCR4-directed therapeutic approaches in MM
and other diseases.
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Introduction
Chemokine receptor-4 (CXCR4) is a member of the G-protein-
coupled chemokine receptor family. The sole known natural ligand
of CXCR4 is CXCL12/SDF-1. SDF-1 binding to CXCR4 activates
downstream signaling pathways such as MAP kinase and the PI3
kinase pathway, ultimately resulting in altered cell adhesion, migra-
tion, and homing (Zlotnik et al, 2011; Jacobson & Weiss, 2013).
CXCR4 is normally expressed on T and B lymphocytes, monocytes,
macrophages, neutrophils, and eosinophils, and by hematopoietic
stem/progenitor cells (HSPCs) residing within the bone marrow
(BM) niche. Antagonizing the CXCR4-mediated retention of HPCs in
this niche by means of anti-CXCR4-directed treatment with the
CXCR4 antagonist plerixafor allows mobilization of HPCs for auto-
grafting upon myeloablative therapies (Brave et al, 2010). Plerixafor
treatment also mobilizes various lymphocyte populations into the
peripheral blood, emphasizing the important role of the SDF-1/
CXCR4 axis for lymphocyte trafficking (Kean et al, 2011).
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Pathological CXCR4 overexpression has been reported in various
types of solid cancers and in hematopoietic malignancies such as
leukemia and lymphoproliferative malignancies (Burger & Peled,
2009; Cojoc et al, 2013). In cancer, CXCR4 overexpression and recep-
tor activation by SDF-1 binding are key triggers for tumor growth and
progression, invasiveness, and metastasis (Muller et al, 2001).
Accordingly, CXCR4 overexpression has been identified as an adverse
prognostic factor in various malignancies (Spano et al, 2004; Spoo
et al, 2007). In particular, CXCR4-mediated interaction that holds
cancer (re-)initiating cells within a protective tumor microenviron-
ment (TME) seems to be responsible for resistance to pharmacological
treatment, and for relapse, at least in hematopoietic cancers (Teicher
& Fricker, 2010; Mendelson & Frenette, 2014; Shain & Tao, 2014).
Multiple myeloma (MM, plasma cell myeloma) is the second most
prevalent B-cell cancer. Despite the availability of potent novel drugs,
it remains, for the large part of patients, an incurable disease (Palumbo
& Anderson, 2011; Ocio et al, 2014). MM is characterized by the
expansion of malignant plasma cells predominantly within the BM.
One key clinical characteristic is the uncoupling of bone formation and
bone destruction, resulting in osteolytic bone lesions (Raab et al,
2009; Roodman, 2010). Studies on both cultured and patients’ primary
MM cells showed a strong correlation between CXCR4/SDF-1 activa-
tion and MM-related bone disease (Zannettino et al, 2005; Bao et al,
2013). SDF-1 engages CXCR4 on MM cells favoring their recruitment
to the BM by affecting migration, adhesion, and extravasation (Parmo-
Cabanas et al, 2004; Aggarwal et al, 2006; Alsayed et al, 2007).
Besides the different cell types constituting the BM niche, primary MM
cells themselves secrete SDF-1, which results in autocrine stimulation
of plasma cell proliferation. Therefore, the CXCR4/SDF-1 axis repre-
sents a highly relevant molecular target in MM and other cancers due
to its important role in pathogenesis and its potential involvement as a
mediator of resistance to treatment (Burger & Kipps, 2006).
Despite the fundamental role of CXCR4 in cancer and in particular
MM biology and its significance as a target for therapeutic approaches,
a highly sensitive method for CXCR4 assessment and quantification
in vivo has been lacking so far. Such in vivo assessment of CXCR4
expression could provide an additional and clinically important method
to select patients for CXCR4-directed treatment, for example, by anti-
CXCR4 antibodies that are in early-phase clinical trials (Kashyap et al,
2012) (e.g., ClinicalTrials.gov identifier NCT01359657), or for use
within a theranostic peptide receptor radiotherapy (PRRT) concept. To
meet this clinical need, [68Ga]Pentixafor ([68Ga]CPCR4.2), a high-
affinity CXCR4-targeted nuclear probe for PET imaging, has recently
been developed (Demmer et al, 2011; Gourni et al, 2011) and evalu-
ated in a first proof-of-concept investigation (Wester et al, 2015). The
present study aimed at the evaluation of [68Ga]Pentixafor PET/CT as a
novel and powerful tool for sensitive, non-invasive in vivo quantifica-
tion of CXCR4 in preclinical models of MM and in a clinical pilot
assessment investigating patients with advanced MM.
Results
Frequency of MM patients with high tumor
CXCR4 (CD184) expression
The CXCR4-SDF-1 axis constitutes a central mechanism for recruit-
ing and retaining MM cells within the TME (Zannettino et al, 2005;
Bao et al, 2013). To investigate the frequency of MM patients with
high CXCR4 expression, we performed flow cytometry on an unse-
lected cohort of 25 patients undergoing BM biopsy for previously
established MM, or because of newly diagnosed monoclonal gammo-
pathy. By assessing CXCR4 expression as compared to an isotype
control antibody (gating strategy depicted in Supplementary Fig S1),
we identified 14 of 25 patients (56%) with CXCR4-positive MM.
Representative histograms depicting CXCR4+ vs. CXCR4 MM are
shown in Fig 1A.
In order to estimate the magnitude of CXCR4 expression in
MM cells compared to normal non-malignant cell populations
that have previously been described as CXCR4 positive (Aiuti
et al, 1999; Honczarenko et al, 1999; Burger & Kipps, 2006;
Brave et al, 2010), we compared CXCR4 expression levels in
individual MM patient samples judged CXCR4 positive by flow
cytometric and immunohistochemical assessment (CXCR4+ MM).
In CXCR4+ MM, relative plasma cell surface CXCR4 expression
levels were significantly higher than those on intraindividual
CD19+ B cells, CD3+ T cells, CD34+ HSPCs, and CD14+ mono-
cytes (Fig 1B–D; gating strategy depicted in Supplementary
Fig S1; representative data shown in Supplementary Fig S2A–D),
indicating that a CXCR4-directed PET tracer could be suitable
for MM imaging.
Thus, in our unselected cohort, over 50% of MM patients
expressed CXCR4 on their plasma cells. Relative cancer cell CXCR4
expression in these patients was high compared to intraindividual
control BM cell populations.
[68Ga]Pentixafor is a PET tracer suitable for detecting CXCR4+
MM in vivo
Considering the high CXCR4 expression levels in a substantial
proportion of MM patients as compared to intraindividual control
cell populations, we searched for MM cell lines that could be suited
for preclinical in vivo imaging studies. Considerable levels of CXCR4
transcript (Fig 2A) and protein (Fig 2B) were detected in the
well-established MM lines MM.1S and OPM-2 as opposed to the
ovarian cancer cell line HeLA, which is characterized by low CXCR4
expression. Moreover, MM.1S and OPM-2 cells were found to bind
the CXCR4-directed PET probe [68Ga]Pentixafor (Fig 2C). Thus,
these cell lines represent models for in vivo binding and uptake
studies.
In order to determine the suitability of the high-affinity human
CXCR4-specific probe Pentixafor as an in vivo MM PET tracer,
NOD SCID mice were xenografted with MM.1S and OPM-2 cells
and underwent consecutive [18F]FDG and [68Ga]Pentixafor PET.
Imaging with [68Ga]Pentixafor resulted in markedly higher mean
tumor-to-background ratios (TBR) for both the MM.1S and OPM-2
xenografted tumors, compared to the widely used tracer [18F]FDG
(Fig 2D and E). Flow cytometric quantification of cell surface
CXCR4 expression on resected tumors suggested a correlation
between CXCR4 cell surface levels and the [68Ga]Pentixafor uptake
in the respective xenografts observed in the small animal PET
studies (Fig 2F and G). As expected when using a human CXCR4-
specific probe such as Pentixafor (Gourni et al, 2011), virtually no
tracer uptake was observed in CXCR4-expressing mouse organs
such as spleen, lung, adrenals, or the BM (Fig 2E). To further
substantiate the specificity of [68Ga]Pentixafor binding to human
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CXCR4, we next performed competition studies where mice bear-
ing MM xenograft tumors received the FDA-approved drug
AMD3100 (Plerixafor) (Brave et al, 2010) before receiving the
[68Ga]-labeled PET probe. AMD3100 pretreatment resulted in a
near complete loss of [68Ga]Pentixafor binding in vitro and in vivo
(Fig 2H, Supplementary Fig S3).
Thus, [68Ga]Pentixafor is a PET tracer that binds human
CXCR4 expressed on MM cell lines and xenograft tumors with
high specificity and is suitable as an in vivo CXCR4 PET imaging
probe.
[68Ga]Pentixafor provides additional diagnostic information to
[18F]FDG in MM patients
To evaluate the suitability of [68Ga]Pentixafor for in vivo imaging
of MM in patients and for its usefulness to select patients for
future CXCR4-directed treatments, we visually analyzed 14
patients with histologically proven, advanced MM. The patient
characteristics are shown in Table 1. All patients gave written
informed consent for receiving the [68Ga]Pentixafor PET as well
as undergoing a standard [18F]FDG PET. Representative images of
one [68Ga]Pentixafor PET-positive patient are shown in Fig 3A–D.
Representative images of one [68Ga]Pentixafor PET-negative
patient are shown in Supplementary Fig S4. In summary, 9 of 14
(64%) [18F]FDG scans were rated visually positive, whereas 10 of
14 (71%) [68Ga]Pentixafor scans revealed disease manifestations
(Fig 4A). Visual comparison of [18F]FDG and [68Ga]Pentixafor
scans resulted in comparable findings in 3 (21%) patients. In
7 patients (50%), the [68Ga]Pentixafor signal was superior to
[18F]FDG identifying more tumor lesions, whereas in 2 patients
(14%), [18F]FDG provided additional information compared to
[68Ga]Pentixafor. In the remaining 2 patients (14%), [68Ga]Pentixafor
and [18F]FDG provided complementary information regarding the
detection of myeloma manifestations (Fig 4B). More than three
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Figure 1. CXCR4 expression in MM patient bone marrow.
A Flow cytometric evaluation of CXCR4 surface expression using an anti-CXCR4-PE antibody. Left: positive patient; right: negative patient; representative data are
shown. The gating strategy is depicted in Supplementary Fig S1.
B Representative histograms revealing the magnitude of CXCR4 expression in myeloma cells as compared to the indicated bone marrow cell subtype.
C Median fluorescence intensity of surface CXCR4 expression relative to isotype control (n = 7–10 patients). Horizontal bars indicate mean of all individual patient
values; asterisks indicate statistical significance (plasma cells vs B cells: P = 0.0082; plasma cells vs T cells: P = 0.0091; plasma cells vs CD34+ cells: P = 0.011; plasma
cells vs monocytes: P = 0.0423; Student’s t-test to compare mean plasma cell relative expression with mean relative expression of each further indicated cell
subtype). MM patients judged positive for CXCR4 expression were selected for this analysis.
D Representative MM bone marrow staining of a patient positive for MM CXCR4 expression: hematoxylin and eosin (H&E) staining. Immunohistochemistry for CD138,
CXCR4, light chain kappa, and light chain lambda.
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lesions were reported in 8 of 14 FDG scans and 8 of 14
[68Ga]Pentixafor PET scans. Extramedullary disease (EMD) was
detected in 3 [68Ga]Pentixafor scans and in 2 [18F]FDG PET
scans. In one patient, [68Ga]Pentixafor but not [18F]FDG identified
EMD. In comparison with the PET scans, only 1 of 14 CT scans
did not show MM manifestations resulting in 13 of 14 (93%)
positive scans. More than three lesions were described in 10 of
14 patients, whereas EMD was only reported in 1 patient. An
exemplary patient where [68Ga]Pentixafor imaging provided supe-
rior information is shown in Supplementary Fig S5.
In summary, combined Pentixafor/FDG PET imaging provides
additional information on disease extent in MM patients.
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Figure 2. [68Ga]Pentixafor PET imaging of MM xenografts.
A Real-time PCR analysis of cxcr4 transcript expression levels in HeLa (negative control) and in MM cell lines MM.1S and OPM-2. Shown is the mean relative
expression  SEM (n = 3 independent experiments). Values are normalized to the expression of ubiquitin (Ub). The asterisk indicates statistically significant
differences (HeLa vs MM.1S: P < 0.001; HeLa vs OPM-2: P < 0.0001; Student’s t-test).
B CXCR4 protein expression assessed by immunoblotting (one representative blot out of 3 is shown).
C Binding of [68Ga]Pentixafor to MM.1S and OPM-2 cells after the indicated incubation periods (n = 3 per cell line and time point). Shown is the mean  SEM. The
difference between the OPM-2 groups is statistically significant; *P < 0.0017 (one-way ANOVA).
D Mean tumor-to-background ratio (TBR) for [18F]FDG (left) and for [68Ga]Pentixafor (right) in MM.1S and OPM-2 xenograft-bearing NOD SCID mice. Shown is the
mean  SEM, n = 8 tumors (4 mice); *P = 0.0111 for [18F]FDG and *P = 0.0113 for [68Ga]Pentixafor (Student’s t-test). One-way ANOVA revealed significant
differences between the groups; P < 0.0001 (not graphically shown).
E Representative [68Ga]Pentixafor PET images of three mice bearing MM.1S (right shoulder) and OPM-2 (left shoulder) tumors.
F Flow cytometric quantification of CXCR4 cell surface expression on resected MM.1S and OPM-2 tumors. Data are the mean  SEM, n = 4. *P = 0.0286;
Mann–Whitney U-test.
G Correlation of [68Ga]Pentixafor PET mean TBR and CXCR4 cell surface expression assessed by flow cytometry. n = 8 tumors were analyzed.
H Mice (n = 4) bearing OPM-2 and MM.1S xenografts were coinjected with AMD3100 (right image, one representative mouse) or not pretreated (left image) before
undergoing [68Ga]Pentixafor PET. The white arrows point to the bladder. Quantification is shown in Supplementary Fig S3A.
Source data are available online for this figure.
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Lesion-based visual and semi-quantitative comparison of [18F]
FDG and [68Ga]Pentixafor uptake
Up to three lesions per patient were semi-quantitatively evaluated
accounting for a total of 32 lesions (3 lesions in ten patients and 2
lesions in one patient). For [18F]FDG, a total of 23 lesions were rated
visually positive as opposed to 26 for [68Ga]Pentixafor. While
17 lesions were read as [18F]FDG and [68Ga]Pentixafor positive,
6 lesions only showed increased [18F]FDG uptake. In contrast,
9 lesions were [68Ga]Pentixafor positive and [18F]FDG negative. The
corresponding mean SUVmax value for [
18F]FDG was 5.5 (range 2.3–
15.7) and thus significantly lower than the mean SUVmax for [
68Ga]
Pentixafor (8.7, range 1.4–33.7; P = 0.018; Wilcoxon signed-rank
test). SUVmax data are summarized in Supplementary Fig S6.
Correlation with standard imaging techniques CT and magnetic
resonance imaging (MRI)
Low-dose CT information was available in all 14 patients revealing
bone involvement in all but one patient (93%). A diagnostic CT with
contrast media was only available in 2 patients, and a diagnostic CT
without contrast media in additional 3 patients. With this limitation
in mind, EMD was only seen in 1 patient. MRI was performed as
part of PET/MRI in two patients showing extended bone disease in
both patients with no EMD. The sensitivity of the [68Ga]Pentixafor
probe for detecting BM infiltration that is not clearly evident as lytic
bone lesions is exemplified in a CXCR4-PET-positive patient, where
the [68Ga]Pentixafor PET showed visual positivity corresponding
well to intramedullary MM infiltration revealed by MRI (Fig 5A–C).
[68Ga]Pentixafor PET is not associated with HSPC mobilization or
blood count variations
Application of [68Ga]Pentixafor was well tolerated. Peripheral blood
was obtained from 7 of 14 patients of the imaging cohort 1 h before
( 1), 1 h (+ 1), 24 h (+ 24), and 7 days (day 7) after [68Ga]Pentixafor
PET imaging. White blood counts, hemoglobin, and platelet counts
were assessed at the indicated time points and did not reveal signifi-
cant intrapatient changes associated with tracer application. We also
did not observe significant changes in peripheral blood CD34+
Table 1. Patient characteristics at initial diagnosis (imaging cohort).
No of
patients %
Median
(range)
14 100
Age 72 (51–84)
Sex
male 11 79
female 3 21
Monoclonal protein
IgG 6 43
IgA 2 14
Light chain kappa 3 21
Light chain lambda 3 21
Stage of disease at first diagnosis
IA 2 14
IIA 1 7
IIIA 5 36
IIIB 6 43
No of previous regimens 4 (1–9)
High-dose chemotherapy 12 86
Radiotherapy 6 43
A B
[18F]FDG 
PET/CT: MIP PET 
[68Ga]Pentixafor 
PET/CT: MIP PET 
[68Ga]Pentixafor
PET/CT: fusion ax 
[18F]FDG 
PET/CT: fusion ax
C
D
Figure 3. [68Ga]Pentixafor PET/CT and [18F]FDG PET/CT.
A–D Maximum intensity projections (MIP) of [68Ga]Pentixafor (A) and [18F]FDG PET/CT (B) of a 68-year-old male with histologically proven multiple myeloma indicating
the better lesion-to-background contrast for [68Ga]Pentixafor in the corresponding myeloma manifestations. Trans-axial views of the upper thorax (C) and the
pelvis (D) underline the higher uptake values of the bone manifestations (yellow arrows) of [68Ga]Pentixafor compared to [18F]FDG.
ª 2015 The Authors EMBO Molecular Medicine Vol 7 | No 4 | 2015
Kathrin Philipp-Abbrederis et al In vivo CXCR4 imaging of human myeloma EMBO Molecular Medicine
481
proportion nor absolute number (Supplementary Fig S7). No further
toxicities were observed during or after [68Ga]Pentixafor applica-
tion.
Discussion
Our data represent the first study on quantitative PET imaging of
CXCR4, a key chemokine receptor involved in leukocyte attraction,
hematopoietic stem cell homing, tumorigenesis, and many other
processes, in preclinical models of myeloma and in a cohort of
patients with advanced MM.
High CXCR4 expression has been reported in numerous solid
cancers and in various hematopoietic malignancies, including MM
(Teicher & Fricker, 2010; Weilbaecher et al, 2011). Importantly, the
level of CXCR4 expression assessed by either transcript or whole-cell
protein-level analysis is not necessarily representative of CXCR4
expression level on the cell surface (Teicher & Fricker, 2010).
CXCR4 overexpression on the cell membrane is, however, the key
parameter for successful CXCR4-directed tumor targeting in vivo,
both for diagnostic imaging and in particular for endoradiotherapeu-
tic approaches. Our in-depth analysis of intraindividual surface
CXCR4 levels in BM subpopulations revealed that in at least half of
the patients, CXCR4 expression on the surface of MM cells is signifi-
cantly elevated as compared to B and T cells, monocytes, and
CD34+ HSPCs. Negligible levels of CXCR4-specific binding were
also observed in normal BM and the main lymphatic organs spleen,
thymus, and lymph nodes. Thus, given the high contrast obtained
in [68Ga]Pentixafor PET between low endogenous CXCR4 expres-
sion and pathological CXCR4 overexpression of positive MM lesions,
this imaging methodology may allow for selecting patients for
CXCR4-directed treatment, such as radionuclide or toxin-labeled
Pentixafor analogs. In accordance with the frequent and strong pres-
ence of CXCR4 on plasma cells from MM patients, CXCR4 expres-
sion on transcriptional and protein level in established human MM
cell lines was robust and [68Ga]Pentixafor was found to bind to
these cells in vitro. Additionally, lPET imaging with Pentixafor
detected xenografted MM tumors with high specificity and contrast,
and tracer accumulation was found to correlate with CXCR4 cell
surface expression in tumor tissue. Thus, detection and investiga-
tion of MM lesions in vivo seems to be feasible with [68Ga]Pentixafor.
However, the high tumor/background ratios observed in the mouse
xenograft model are at least partly the result of the selectivity of
[68Ga]Pentixafor for human CXCR4 (Demmer et al, 2011). Since
[68Ga]Pentixafor does not bind to murine CXCR4, [68Ga]Pentixafor
PET studies investigating CXCR4-associated pathologies in a mouse
model are currently limited to xenograft animal models.
High levels of CXCR4 have been shown to indicate particularly
aggressive disease, metastasis, or poor prognosis in solid cancers
(Teicher & Fricker, 2010; Weilbaecher et al, 2011) and AML (Spoo
et al, 2007). Such correlations are, however, not expected in MM, a
malignancy that is at primary diagnosis nearly exclusively BM based
(Raab et al, 2009; Roodman, 2010; Palumbo & Anderson, 2011; Ocio
et al, 2014). Although CXCR4/SDF-1 activation and MM-related
bone disease are clearly associated (Zannettino et al, 2005; Bao
et al, 2013), it is evident that SDF-1 engages CXCR4 on MM cells
favoring their recruitment to the BM by affecting migration, adhe-
sion, and extravasation (Parmo-Cabanas et al, 2004; Aggarwal et al,
2006; Alsayed et al, 2007). Thus, losing the requirement for
MM–TME interactions in situations like plasma cell leukemia or in
extramedullary relapse could point to a scenario where
[68Ga]Pentixafor PET might be inferior to standard [18F]FDG PET,
which has proven diagnostic value in extramedullary MM (Bao
et al, 2013; Stessman et al, 2013). Although we investigated such
patients with EMD after allogeneic SCT with both PET tracers, it is
to date not clear whether this is the case. Our data, however,
suggest a possible complementary benefit when both PET tracers
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Figure 4. Visual comparison of [18F]FDG- and [68Ga]Pentixafor PET scans.
A Number of patients with visual positivity for the indicated PET tracer (total:
n = 14).
B Number of patients (total n = 14) for whom imaging with [18F]FDG PET
(FDG, n = 2) or [68Ga]Pentixafor PET (Pentixafor, n = 7) was superior, with
comparable positivity (comparable, n = 3), and with dual imaging providing
complementary visual information (complementary, n = 2).
CT
[68Ga]Pentixafor
PET/MR MR-T2stir
A CB
Figure 5. [68Ga]Pentixafor PET/MR images.
A–C Coronal views of [68Ga]Pentixafor (A), T2 STIR weighted MRI (B) and CT
bone window (C) of a male patient with histologically proven multiple
myeloma. The increased [68Ga]Pentixafor uptake correlates with the
hyperintense T2 STIR signal; however, the myeloma manifestations are
underestimated in the corresponding bone window CT.
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are available. For example, [68Ga]Pentixafor did not penetrate the
intact blood–brain barrier, in sharp contrast to FDG.
The CXCR4 antagonist Plerixafor is an FDA- and EMA-
approved drug used for mobilization of HSPCs for stem cell graft
retrieval (Brave et al, 2010). The dosage used for this purpose is
0.24 mg/kg body weight per day, in combination with granulocyte
colony-stimulating factor (G-CSF), and usually applied after several
days of G-CSF treatment alone. As expected on the basis of the
applied amount of Pentixafor (< 20 lg/patient), we did not
observe any side effects of [68Ga]Pentixafor application acutely or
during the course of several days, in particular any blood count
or HSPC abnormalities other than caused by the underlying MM.
Also, toxicity of the radionuclide 68Ga in the administered dose is
negligible. Previous efforts to use Plerixafor-derived probes for
imaging purposes failed due to an accumulation of the drug in
spleen tissue, or by unspecific binding within liver tissue or
liver-based metabolism (Nimmagadda et al, 2009, 2010; De Silva
et al, 2011; Kuil et al, 2012; Weiss & Jacobson, 2013). In none of
our patients did we find evidence of increased binding of
[68Ga]Pentixafor in the liver that was not associated with MM as
documented with the established PET tracer [18F]FDG.
In the vast majority of cases, MM presents as a systemic disease
with a measurable monoclonal gammopathy that allows following
response to treatment and observing the patient for relapse non-
invasively (Rajkumar et al, 2011). Analysis of serum and urine by
means of immunofixation allows for the detection of subclinical
disease, and low-dose whole-body computed tomography is a
powerful tool for the detection of osteolytic lesions which may
prompt initiation of radiotherapy planning (Ippolito et al, 2013).
Magnetic resonance imaging (MRI) provides more detailed infor-
mation about BM infiltration and EMD in MM (Baur-Melnyk et al,
2005), and [18F]FDG PET imaging clearly provides additional infor-
mation with regard to prognosis and extent of local disease, in partic-
ular EMD (Durie et al, 2002; Zamagni et al, 2011; Agarwal et al,
2013). Both MRI and [18F]FDG PET are, however, not considered a
routine procedure required for every patient (Rajkumar et al, 2011).
The purpose of this study was thus not to establish a novel diagnostic
PET tracer for MM in particular, but to test the applicability of this
molecular probe in a disease with frequent CXCR4 surface
expression. More importantly, however, we consider MM a disease
where it would be highly interesting to combine [68Ga]Pentixafor
PET as a selection marker for CXCR4-directed treatment and to
ensure target expression. Upon availability, [177Lu]- or [90Y]-coupled
Pentixafor analogs could become attractive radiopharmaceuticals for
a theranostic approach with 68Ga-labeled Pentixafor as a marker for
patient selection and therapy monitoring, and the latter compounds
as endoradiotherapeutics. Such an approach has previously been
demonstrated in neuroendocrine tumors with resounding success
(Breeman et al, 2003; Das et al, 2007; Werner et al, 2014). The most
obvious and attractive scenario would thus follow the sequence
[68Ga]Pentixafor PET, therapy with a radionuclide or toxin, a stan-
dard myeloablative therapy, followed by SCT. SCT thus would allow
applying labeled Pentixafor doses that will most likely result in
perturbations of BM function. Such an approach is currently under
investigation. Also, disintegrating and targeting the HSC interaction
with its BM niche could be an interesting principle in treating HSPC
disorders (Burger et al, 2009; Shain & Tao, 2014). In addition to such
direct usage of Pentixafor as a carrier for active agents, the use as an
imaging modality for patient selection would be an obvious
approach, for example, for anti-Notch-directed treatments that are
currently being evaluated and involve CXCR4-SDF-1 activation
(Mirandola et al, 2013), or for selection of patients receiving anti-CXCR4
therapies such as BMS-936564/MDX-1338, a fully human anti-CXCR4
antibody currently in clinical investigation (Kuhne et al, 2013).
Our data demonstrate the suitability of [68Ga]Pentixafor for PET
imaging of CXCR4 chemokine receptor expression in MM patients.
We conclude that this novel PET tracer could serve as an innovative
imaging agent, for in vivo biomarker identification that could result
in patient selection for CXCR4-directed treatments, and eventually
for receptor-radio(drug)peptide therapy.
Materials and Methods
Patients
Detailed characteristics for the PET imaging patient cohort are given
in Table 1. All patients had histologically proven MM and active
ongoing disease as assessed by biopsy or immune electrophoresis.
As previously reported for other [68Ga]-labeled peptides (Haug et al,
2014), [68Ga]Pentixafor was administered under the conditions of
pharmaceutical law (The German Medicinal Products Act, AMG §13
2b) according to the German law and in accordance with the respon-
sible regulatory agencies (Regierung von Oberbayern, Regierung
von Unterfranken). All patients gave written informed consent prior
to the investigations. The responsible ethics committees of the Tech-
nische Universita¨t Mu¨nchen and the Universita¨tsklinikum Wu¨rzburg
approved data analysis.
The current study is not a confirmatory one. There were no
prespecified hypotheses that would have allowed for sample size calcu-
lation. It is an observational pilot study used to conduct explorative
analyses. Therefore, the sample size was chosen to serve this purpose.
It enabled the computation of descriptive and explorative statistics.
Cell lines and cell culture
The human multiple myeloma cell lines OPM-2 (DSMZ no. ACC50)
and MM.1S (ATCC CRL-2974) were cultured in RPMI 1640 supple-
mented with 10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate,
100 U/ml penicillin, and 100 lg/ml streptomycin. HeLa cells were
cultured in DMEM supplemented with 10% FCS, 100 U/ml penicil-
lin, and 100 lg/ml streptomycin. Cells were maintained at 37°C in a
5% CO2 humidified atmosphere. All media and supplements were
obtained from Invitrogen (Darmstadt, Germany).
Mice and tumor xenograft experiments
Animal studies were performed in agreement with the Guide for
Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996), in
compliance with the German law on the protection of animals, and
with approval of the responsible regional authorities (Regierung von
Unterfranken). NOD.CB17-Prkdcscid/NCrHsd mice were bred at the
animal facility at the Center of Experimental and Molecular Medi-
cine (ZEMM) of the University of Wu¨rzburg. Equally housed and
fed female mice of same size and age were randomly distributed
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into experimental groups. A total of 5 × 106 MM.1S or OPM-2 cells
in 100 ll PBS were injected subcutaneously into the shoulder region
of approximately 8-week-old animals. Tumor growth was monitored
using a shifting calliper. Imaging experiments were initiated when
tumor size reached 200–300 mm3. Mouse experiment samples sizes
were chosen to allow descriptive and explorative statistical analysis.
RNA and protein extraction, real-time PCR and immunoblotting
RNA extraction was performed using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). cDNA synthesis was performed using the Omni-
script RT Kit according to the manufacturer’s protocol (Qiagen,
Hilden, Germany). Real-time PCR was performed using Platinum
SYBR-Green qPCR SuperMix-UDG (Invitrogen) on an ABI Prism
7700 (Applied Biosystems). Data analysis was performed by
comparing Ct values with a control sample set as 1. Sequences for
primers are available upon request. Protein extracts (30 lg per lane)
were electrophoretically separated on a SDS–PAGE gel, transferred
to membranes (Millipore, Darmstadt, Germany), and blotted with
antibodies specific for CXCR4 (clone UMB2; Abcam, Cambridge,
UK) and b-actin (clone AC-74; Sigma-Aldrich, Taufkirchen,
Germany).
Flow cytometry
White blood cell counts, hemoglobin and platelet counts were
measured using an Advia 120 (Siemens, Erlangen, Germany).
Blood samples from the patients of the imaging cohort were
collected in heparin and filtered. Circulating CD34+ cell counts were
assessed in peripheral blood by standardized and certified single-
platform flow cytometry on a Cytomics FC 500 analyzer (Beckman
Coulter, Krefeld, Germany) at four different time points. Cells were
stained with antibodies to CD34 and CD45 (Stem-Kit IM 3630, clone
581; CD45-ECD, clone J33; Beckman Coulter).
Bone marrow samples from an unselected MM patient cohort
were collected in heparin tubes and filtered. These analyses were
performed upon signed informed consent of all patients to analysis
of samples for scientific purposes in an anonymized fashion only.
Cell populations of interest were selected by sequential gating using
Kaluza Flow Analysis Software (Beckman Coulter). The gating strat-
egy is based on CD45 staining versus side-angle light scatter (SSC)
properties as a primary gate to separate CD45-positive lymphocytes,
monocytes, and CD45low progenitors from CD45-negative plasma
cells. Plasma cells were then identified by CD45/CD38 gating and
CD19 negativity. Colored back-gating was used to ensure correct
gating of all subpopulations. For statistical data analysis, intensity
of the isotype control on each subpopulation was subtracted from
the median fluorescence intensity of surface CXCR4 expression in
that population. Details on the gating strategy used are given in
Supplementary Figs S1 and S2. The following antibodies were used:
Beckman Coulter: CD20-ECD (clone B9E9), CD45-ECD (clone J33),
CD3-PC5 (clone UCHT1), CD138-PC5 (clone BB4), CD14-PC5 (clone
RM052), CD34-FITC (clone 581), CD38-FITC (clone T16), CD19-PC7
(clone J4.119), CD56-PC7 (clone N901), and CD33-PC7 (clone
D3HL60.251); BD Pharmingen: CXCR4-PE (clone 12G5).
Surface CXCR4 levels of xenografted human MM cell lines were
determined by flow cytometry (BD FACSCalibur, Beckton-Dickinson,
Heidelberg, Germany) using an anti-CXCR4-PE antibody (hCD184;
clone 12G5; Miltenyi, Bergisch-Gladbach, Germany) according to
the manufacturer’s instructions. Data were analyzed using CellQuest
software (Beckton-Dickinson).
Synthesis of [68Ga]Pentixafor
Synthesis of [68Ga]Pentixafor was performed at both centers in a
fully automated, GMP-compliant procedure using a GRP module
(SCINTOMICS GmbH, Germany) equipped with disposable single-
use cassette kits (ABX, Germany), using the method (Demmer,
Gourni et al, 2011 and Gourni, Demmer et al, 2011) and standard-
ized labeling sequence previously described (Martin et al, 2014).
Prior to injection, the quality of [68Ga]Pentixafor was assessed
according to the standards described in the European Pharmaco-
poeia for [68Ga]-Edotreotide (European Pharmacopoeia; Monograph
01/2013:2482; available at www.edqm.eu).
In vitro binding study
Binding of [68Ga]Pentixafor to MM.1S and OPM-2 MM cells was
investigated using a modified standard protocol (Lu¨ckerath et al,
2013). Briefly, 4 × 105 cells in 500 ll PBS were incubated with
1 × 106 counts per minute (cpm) radiotracer/50 ll PBS (equaling
approximately 1 nM peptide per sample) for the indicated times.
After the removal of unbound tracer and washing with PBS, binding
of [68Ga]Pentixafor was quantified using a gamma-counter
(Wallac1480-Wizard, Perkin-Elmer, Rodgau, Germany). All samples
were measured in triplicate and corrected for background activity
and decay. For competition experiments, MM cell lines were
pretreated for 30 min with AMD3100 100 lM (Selleck Chemicals,
Houston, TX, USA, ordered from Absource Diagnostics GmbH,
Munich, Germany) before being objected to [68Ga]Pentixafor uptake
analysis.
In vivo CXCR4 imaging of mice
Positron emission tomography scans of xenotransplanted MM.1S
and OPM-2 tumors in NOD.CB17-Prkdcscid/NCrHsd mice were
performed as previously described (Graf et al, 2014). Briefly, mice
were intravenously injected with 2.5 MBq/mouse [68Ga]Pentixafor
or 9 MBq/mouse [18F]FDG and static images were acquired for
15 min starting 1 h post-injection on a lPET system (Inveon,
Siemens, Erlangen, Germany). All mice received a [68Ga]Pentixafor
PET scan and a second one with [18F]FDG the following day.
Tumor-to-background ratios of tracer intensity were calculated by
placing three-dimensional regions of interest within the tumors and
in healthy tissue (background). In competition imaging assays,
AMD3100 (2 mg/kg body weight, Selleck Chemicals) was intrave-
nously injected immediately before [68Ga]Pentixafor was injected.
PET scans were acquired 1 h post-PET tracer injection.
PET/CT and PET/MR imaging studies
All [18F]FDG scans and 12/14 [68Ga]Pentixafor scans were
performed on dedicated PET/CT scanners (Siemens Biograph mCT
64; Siemens Medical Solutions, Germany), whereas 2 of 14 [68Ga]
Pentixafor scans were performed on a PET/MRI device (Siemens
Biograph mMR; Siemens Medical Solutions, Germany). Before
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acquisition of [18F]FDG PET scans, patients fasted for at least 6 h
prior to injection of a standard dose of 4.5 MBq per kg body weight.
[18F]FDG was only injected if blood glucose levels were < 180 mg/dl.
Prior to [68Ga]Pentixafor scans, patients fasted for at least 4 h.
Injected activities ranged from 90 to 205 MBq. Corresponding CT
low-dose scans for attenuation correction were acquired using a
low-dose protocol (20 mAs, 120 keV, a 512 × 512 matrix, 5 mm
slice thickness, increment of 30 mm/s, rotation time of 0.5 s, and
pitch index of 0.8) including the base of the skull to the proximal
thighs. In PET/MR, first a coronal 2-point Dixon 3D volumetric
interpolated examination (VIBE) T1 weighted (T1w) MR sequence
was performed for generation of attenuation maps as recently
published (Drzezga et al, 2012). In addition, both a coronal T1 TSE
(TR/TE 600/8.7, slice thickness 5 mm, matrix 384 × 230) and a
T2w STIR (short s inversion recovery) sequence with fat suppres-
sion (TR/TE/TI 5,000 ms/56 ms/220 ms, slice thickness 5 mm,
matrix 106 × 256) were acquired. Consecutively, PET emission data
were acquired in three-dimensional mode with a 200 × 200 matrix
with 2–3 min emission time per bed position. After decay and
scatter correction, PET data were reconstructed iteratively with
attenuation correction using a dedicated software (Siemens Esoft).
PET, CT and MR analysis
All CT and MRI scans were scored by a board-certified radiologist,
and all PET scans were scored by a board-certified nuclear medicine
physician. All PET scans were interpreted in a binary visual fashion
as positive for disease or negative for disease according to the crite-
ria previously described (Zamagni et al, 2011). Briefly, the presence
of focal areas of detectable increased tracer uptake within bones
(e.g., more intense than background bone marrow (BM) uptake
excluding articular processes, with or without any underlying lesion
identified by CT) were rated positive. If the scan was rated as posi-
tive, disease manifestations were rated as either intra- and/or extra-
medullary. Intramedullary disease was then separately assessed for
13 regions including head, spine (cervical, thoracic, lumbar),
sacrum, pelvis (left and right), upper (left and right) and lower (left
and right) extremities, as well as rib cage (left and right). Involve-
ment of the sternum went along in all patients with rib cage
manifestations and was therefore not separately assessed.
Semi-quantitative analysis comprised calculation of maximum stan-
dardized uptake values (SUVmax) as well as SUVmean by 2D ROIs
with a diameter of 1.5 cm around the hottest pixel. Up to 3 lesions
were recorded, if subjects presented with more than 3 focal lesions
(FL); they were categorized into the subgroup > 3 FL. Lesions in the
appendicular skeleton were divided from those in the axial portions.
Diffuse BM involvement was considered if the tracer uptake was
diffusely increased with a SUVmax equal to, or greater than, the
uptake in the spleen. The presence of extramedullary disease
(EMD), defined as [18F]FDG-avid tissue that, according to CT exami-
nation, was not contiguous to bone and arose in soft tissue, was
described by location and number of lesion. Paramedullary disease
arising from bone was considered as a lesion but not as EMD.
CT and MR scans were read as outlined previously (Angtuaco
et al, 2004). In CT, any osteolytic changes not related to degenera-
tive or other benign changes (e.g., hemangioma) were rated as
suspicious for MM. In MR, any focal lesion presenting with low
signal intensity on T1w TSE images (signal intensity not higher than
surrounding muscle) and high signal intensity on T2-weighted
sequences and STIR images were judged as suspicious for MM. For
intramedullary disease, the same regions were rated as in PET. In
addition, any extramedullary lesions defined by extramedullary soft-
tissue formations were noted.
Immunohistochemistry and immunofluorescence of patient
biopsy material
For immunohistochemistry, the following antibodies were used:
anti-CD138 mouse (B-A38) monoclonal antibody (Cell Marque, CA,
USA) and anti-CXCR4 rabbit polyclonal antibody (Abcam). After
deparaffinization and rehydration, the slides were placed in a
pressure cooker in 0.01 M citrate buffer (pH 6.0) and were heated
for 7 min. Incubation with the different antibodies was carried out
overnight at 4°C. Detection was performed with DAKO en vision
system according to the manufacturer0s protocol. For double
immunofluorescence, primary antibodies were detected by incuba-
tion with the following secondary antibodies: donkey anti-rabbit
conjugated with Dylight 488 (Jackson ImmunoResearch, Suffolk,
UK) and donkey anti-mouse conjugated with Cy5 (Jackson Immuno-
Research). After incubation of slides with conjugated secondary
antibody for 30 min, slides were counterstained and mounted with
mounting medium (Vectashield, Vector laboratories, Burlingame,
CA, USA).
Statistical analysis
All statistical tests were performed using SPSS Statistics version 22
(IBM) or GraphPad Prism (GraphPad Software). P-values < 0.05
The paper explained
Problem
Malignancies of the hematopoietic or lymphoid tissues are mostly
considered systemic diseases involving the whole body. Therefore,
systemic treatment approaches are applied, for example, classical
chemotherapy or novel drugs. Cancer cells evade such potentially
effective and curative treatment by localizing to a putative protective
niche, from where relapse is thought to occur. The chemokine/
chemokine receptor axis SDF-1alpha/CXCR4 is a major determinant
for recruiting cancer cells to this protective niche.
Results
Here, we provide the first evaluation of in vivo CXCR4 imaging in a
series of patients with a particular cancer of the lymphoid system,
multiple myeloma, using the CXCR4-specific PET tracer Pentixafor in
comparison with the clinically established tracer FDG. We identify
myeloma manifestations that are positive for CXCR4 uptake and
establish the use of an in vivo biomarker imaging technique for future
therapeutic/theranostic purposes.
Impact
Our findings identify the CXCR4 PET tracer Pentixafor as a novel
tool for in vivo imaging of multiple myeloma. This tracer is suitable
for identifying patients who could be treated with CXCR4-directed
drugs, thus reflecting an in vivo biomarker. Labeling of Pentixafor
or derived peptides with radionuclides or drug conjugation seems
suitable for therapeutic targeting of the cancer cell and its protect-
ing niche.
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were considered statistically significant. Quantitative values were
expressed as mean  standard deviation or standard error of the
mean (SEM) or standard deviation (SD) as indicated. Comparisons
of related metric measurements were performed using Wilcoxon
signed-rank test, and the Mann–Whitney U-test or Student’s t-test
was used to compare quantitative data between two independent
samples. Analysis of variance (ANOVA) statistical test was used to
analyze the differences between group means.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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